Evidence map›Paper›PMID 42877975›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2026

Human Genetics of Adipose Dysfunction: Genomic Mechanisms and Therapeutic Opportunities in Cardiometabolic Disease.

Elizabeth A Burton, Victor Svenstrup, Mayank Murali, Hesam Dashti, Ruth J F Loos, Melina Claussnitzer

Abstract readReview
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elizabeth A Burton *Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of Harvard and MIT, Cambridge, MA (E.A.B., V.S., M.M., H.D., R.J.F.L., M.C.).ORCID 0000-0002-8376-9282
Victor Svenstrup *Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of Harvard and MIT, Cambridge, MA (E.A.B., V.S., M.M., H.D., R.J.F.L., M.C.).ORCID 0009-0002-5725-8865
Mayank MuraliNovo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of Harvard and MIT, Cambridge, MA (E.A.B., V.S., M.M., H.D., R.J.F.L., M.C.).
Hesam DashtiNovo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of Harvard and MIT, Cambridge, MA (E.A.B., V.S., M.M., H.D., R.J.F.L., M.C.).
Ruth J F LoosNovo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of Harvard and MIT, Cambridge, MA (E.A.B., V.S., M.M., H.D., R.J.F.L., M.C.).ORCID 0000-0002-8532-5087
Melina ClaussnitzerNovo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of Harvard and MIT, Cambridge, MA (E.A.B., V.S., M.M., H.D., R.J.F.L., M.C.).ORCID 0000-0003-2450-736X

Funding

Investigating Human Adipocyte HeterogeneityRC2DK116691 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Orr Ashenberg, Noel P Burtt · 2018 to 2026
$17.8M
Bridging the gap between type 2 diabetes GWAS and therapeutic targetsUM1DK126185 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLAUSSNITZER, MELINA C, GLOYN, ANNA LOUISE · 2020 to 2024
$9.5M
Resources to interpret genetic signals and multi-tissue mechanisms for type 2 diabetes and related traitsRC2DK144819 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melina C Claussnitzer, Anna Louise Gloyn · 2025 to 2026
$3.2M
NIDDK NIH HHS RC2 DK116691NIDDK NIH HHS RC2 DK144819NIDDK NIH HHS UM1 DK126185
6 · The paper itself

Abstract

Cardiometabolic diseases are a leading cause of global morbidity and mortality and arise from shared and distinct risk factors acting through interconnected biological pathways. Although excess adiposity is a major risk factor, body mass index incompletely captures cardiometabolic risk, reflecting heterogeneity in overall and regional fat storage capacity and ectopic lipid accumulation. Failure of subcutaneous adipose tissue to expand appropriately promotes lipid overflow into visceral and ectopic depots, contributing to insulin resistance, dyslipidemia, and organ dysfunction. Human genetic studies have identified thousands of genetic loci influencing fat storage, fat distribution, and ectopic lipid accumulation, revealing that these traits reflect distinct underlying mechanisms with divergent cardiometabolic consequences. Recent scaling of genetic discovery for refined adiposity and cardiometabolic phenotypes and multitrait genetic approaches have advanced understanding of adipose-driven disease heterogeneity. We highlight variant-to-function strategies to resolve causal pathways and discuss emerging scalable approaches to accelerate biological learning from genetic discovery and translate these insights into adipose-directed therapeutics for cardiometabolic disease.

Indexed as

cardiovascular diseasesgeneticsinsulin resistancemortalityrisk factors

Identifiers

PMID42877975
PMCPMC13693540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.